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Abstract: A large percentage of drug compounds exhibit low water solubility and hence low 
bioavailability and therapeutic efficacy. This may be addressed by preparation of drug nanoparticles, 
leading to enhanced dissolution rate and direct use for treatment. Various methods have been 
developed to produce drug nanocrystals, including wet milling, homogenization, solution 
precipitation, emulsion diffusion, and the recently developed emulsion freeze-drying. The drawback 
for these methods may include difficult control in particles size, use of surfactants & polymer, and 
low ratio of drug to stabilizer. Here, biocompatible branched block copolymer nanoparticles with 
lightly-crosslinked hydrophobic core and hydrophilic surface groups are synthesized by the direct 
monomer-to-particle methodology, characterized, and then used as scaffold polymer/surfactant to 
produce drug nanoparticles via the emulsion-freeze-drying approach. This method can be used for 
model organic dye and different poorly water-soluble drugs. Aqueous drug nanoparticles dispersions 
can be obtained with high ratio of drug to stabilizer and relatively uniform nanoparticle sizes. 
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1. Introduction 
A report published in 1988 demonstrated that of all pharmaceutical drugs produced in the UK over 
a timeframe of 20 years, 40% exhibited poor bioavailability[1]. New and improved screening methods 
can now predict and eliminate some drug candidates with low bioavailability, before going into 
testing[2]. Still a report published in 2004[3] reported that only 17.1% of all essential drugs defined 
by the world health organisation (WHO) could be classified as BCS II drugs (high permeability and 
low solubility) and 10.6% as BCS IV drugs (low permeability and low solubility), as defined by 
Amidon and co-workers[4]. Low bioavailability is the direct consequence of low water solubility for a 
large percentage of drugs, particularly for BCS II drugs. A promising approach to enhance solubility 
of poorly water-soluble drugs is nanosizing technologies, with the particle sizes in the range of 10 to 
1000 nm[5]. Reducing particle size to nanoscale range enhances both the saturation solubility as 
described in the Oswald-Freundlich equation[6, 7] and the dissolution rate as shown in the Noyes-
Whitney equation[8].  
Both top-down and bottom-up routes have been reported to form nanoparticles. In the top-down 
process, larger drug particles are downsized by mechanical methods, e.g., grinding (wet-media 
milling)[9-12], or by the application of pressure (Piston-Gap)[13-15]. Top-down processes, although 
used more in industry[16], have disadvantages of being time and energy inefficient, difficult to 
produce small nanocrystals and control particle size distribution, and not applicable for hard 
crystalline drugs without pre-treatment. More than one cycle of operation is often required, prone to 
introducing impurities from solvent or milling material[17, 18]. In bottom-up processes the 
nanoparticles are formed from solution, whereby a better control of the crystallisation process can 
lead to smaller particles with narrower particle size distribution. The main obstacle in bottom-up 
approach is repressing and stabilizing against Ostwald-Ripening. A variety of bottom-up methods 
have been described and excellent reviews can be found accordingly [18, 19]. Established and 
industrially applied approaches [19] include solvent-antisolvent precipitation (SAS)[20-22], with its 
variation of high gravity reactive precipitation (HGRP)[23, 24], supercritical fluid precipitation[25-
28] and spray drying[29-31]. Although these techniques have certain advantages, like easy handling 
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(SAS), almost no solvent residue (supercritical fluid) and are more cost and energy efficient, problems 
in stabilizing particle suspensions remain. A solution to this problem, while still maintaining the 
advantages of bottom-up processes, is to rapidly freeze the drug solution and arrest particle growth 
due to freezing. In freeze-drying a solution is frozen and the solvent is subsequently removed in a 
freeze-dryer under vacuum [32-34]. In spray freeze drying, the dissolved material is sprayed into 
liquid nitrogen for downsizing and subsequently freeze dried. This is mainly used for preparation of 
protein particles, which would denature under harsh conditions [35-37].  
    We previously reported the use of emulsion freeze-drying to form organic or drug nanoparticles in 
situ in water-soluble porous polymer. The polymer scaffold prevents the nanoparticles from 
aggregation in the solid state, ensuring a long storage time. The nanoparticles can be readily released 
by dissolving the polymer scaffold in water to produce aqueous nanoparticle dispersion[38]. Both 
polymer (e.g., poly(vinyl alcohol)) and surfactant (e.g., sodium dodecyl sulphate) are required to form 
the emulsions, produce the porous scaffold, and stabilize the nanoparticles in aqueous suspensions. It 
is possible to generate porous polymer by freeze drying and then employ a solvent evaporation 
approach to form organic/drug nanoparticles directly in the porous polymeric scaffold [39, 40]. 
Aqueous nanoparticles dispersion can be prepared similarly. In both approaches, the use of both 
polymer and surfactant is important in forming stable aqueous nanoparticle dispersions. This, 
however, can result in low loading of drug compounds in the formulations. A formulation that utilizes 
a biocompatible polymer acting both as scaffold and surfactant would be advantageous in improving 
drug loading and reducing the formulation complexity (e.g., in assessing biocompatibility).   
    We have also reported synthesis of super-lightly crosslinked branched copolymers and a new direct 
monomer-to-particle synthetic strategy based on these copolymers, which could be applied in drug 
delivery [41-43]. After a simple dialysis process to generate isolated macromolecular species, well-
defined uni-molecular polymer nanoparticles can be obtained directly. This de novo synthetic 
approach differs significantly from the reported arm-first or core-first core-crosslinked star-polymer 
synthesis where the core is effectively a highly cross-linked microgel formed by the addition of a 
large volume of cross-linkers such as divinylbenzene at the end of the polymerisation [44-46]. In 
contrast, polymer nanoparticles were prepared from discrete soluble molecular species (soluble 
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branched copolymers) which have been synthesized by a controlled branching strategy. Utilizing this 
strategy, it was possible to prepare amphiphilic materials with defined nanoparticle shape by a one-
pot, concerted growth process rather than joining of pre-formed spheres [41, 42].  The lightly 
crosslinked core could offer the obtained polymer nanoparticles with larger loading capacity of guest 
compounds. And the stability of the nanoparticles was very high (e.g., up to one year maintaining the 
size and shape). This synthetic methodology may be easily scaled-up as we demonstrated previously, 
even with the possibility to be extended in the synthesis of hyperbranched polydendrons [47]. 
      Herein, we demonstrated for the first time that the branched copolymer nanoparticles (BCN) could 
be used to form stable emulsions without other additives. The branched copolymers applied here were 
the biocompatible poly(ethylene glycol)-b-(N-isopropylacrylamide) (PEG-PNIPAM). The formed oil-
in-water (O/W) emulsions with hydrophobic dyes or drug compounds dissolved in the oil-droplet 
phase were freeze-dried to form nanoparticles in situ within the PEG-PNIPAM scaffold, which can 
then be readily dissolved in water to produce aqueous nanoparticles dispersions.  
 
2. Experimental 
2.1 Chemicals and reagents 
Deionized water was prepared using an AquaMAX-Basic 321 DI water purification system. Oil Red 
O (OR) dye content ≥ 75%, ketoprofen ≥ 98% (TLC), ibuprofen ≥ 98% (HPLC), indomethacin ≥ 99% 
(TLC), o-xylene ≥ 98% (GC), sodium acetate, N-isopropylacrylamide (NIPAM, 97%), and 
dodecanethiol (98%) were purchased from Sigma-Aldrich. Macro-azo poly(ethylene glycol) initiator 
was obtained from Wako Pure Chemical Industries Ltd (Osaka, Japan). Cyclohexane (extra pure) and 
o-xylene were purchased from Fisher scientific and VWR international respectively. All other 
solvents were reagent grade and purchased from Sigma-Aldrich. All chemicals were used as received. 
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2.2 Synthesis of crosslinked branched poly(ethylene glycol)-b-Poly(N-isopropylacrylamide) (PEG-
PNIPAM) 
2.2.1 Synthesis of ethylene diacrylamide 
Ethylene diamine (1.2 g, 20 mmol, 1 eq) and sodium acetate (3.6 g, 40 mmol, 2 eq) were dissolved in 
CHCl3 (50 mL) and the solution cooled to 0 ºC in an ice bath. Acryloyl chloride (3.6 g, 44 mmol, 2.2 
eq) in CHCl3 (50 mL) was then added dropwise over 20 mins. The reaction was left to stir for 1 h at 0 
ºC. The reaction was then refluxed for 1 h at 60 ºC and the solution filtered while hot, upon cooling a 
white precipitate formed which was isolated by filtration. The crude white solid was further purified 
by recrystallization in hot CHCl3 to afford the desired product ethylene diacrylamide as a white solid 
(1.2 g, 36 %). 1H NMR (DMSO-d6): δ 8.19 (s, 2H), 6.19 (m, 2H), 6.07 (m, 2H), 5.58 (m, 2H), 3.21 
(m, 4H). 13C NMR (DMSO-d6): δ 164.9, 131.8, 125.2, 38.4. HRMS (ESI) m/z: [M + H]+ calculated 
for C8H13N2O2, 169.0972; found: 169.0980 (ppm 4.77). 
 
2.2.2 Synthesis of PEG-PNIPAM (1-3) and the corresponding nanoparticle dispersions 
Typically, the radical macro-initiator poly(ethylene glycol) dimer (12 kDa, 1.2 g, 0.1 mmol, 1 eq), N-
isopropylacrylamide (0.56 g, 5 mmol, 25 eq per PEG chain), ethylene diacrylamide (10.1 mg, 0.06 
mmol, 0.3 eq per PEG chain) and dodecanethiol (10.1 mg, 0.05 mmol, 0.25 eq per PEG chain) were 
transferred into a small schlenk tube fitted with a magnetic stirrer bar and N,N’-dimethylformamide 
(DMF,7 mL) added. The reaction mixture was degassed and the vessel was backfilled with N2. The 
reaction mixture was then placed in an oil bath at 70 °C and the polymerization was quenched by 
rapid cooling after 16 h. The reaction mixture was dissolved in a minimal amount of tetrahydrofuran 
(THF) and added dropwise to a large excess of ice-cold diethyl ether. The precipitation was repeated 
once more before the desired branched copolymer was obtained as a white solid (0.94 g). The molar 
ratio of ethylene diacrylamide per PEG chain was varied as 0.3 (1), 0.6 (2), and 0.9 (3) eq per PEG 
change for the PEG-PNIPAM branched block copolymers. Corresponding nanoparticles aqueous 
suspension can be prepared by a simple solvent-removal process. Typically, 10 mg of branched block 
copolymer was dissolved in 5 mL of acetone, followed by addition of 5 mL of water and stirred for 
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0.5 h at room temperature. Acetone was removed by evaporation at room temperature, and final 
transparent nanoparticles aqueous suspension was obtained. 
 
2. 3 Formulation of nanoparticles by emulsion-freeze-drying approach 
Stock solutions of 2 wt% branched block polymer PEG-PNIPAM (0.3, 0.6 and 0.9 cross-linkages as 
synthesized by ethylene diacrylamide of 0.3, 0.6, 0.9 eq per PEG chain) in deionized water and 0.5 
wt% Oil Red O (or indomethacin, ibuprofen, ketoprofen) in cyclohexane (o-xylene) solutions were 
prepared. Cyclohexane and o-xylene were chosen as the organic solvents to dissolve the hydrophobic 
dye/drugs because they are Class 2 solvents for pharmaceuticals with high concentration limits (3880 
ppm and 2170 ppm, respectively) [48]. Both solvents are volatile with high melting points (~ 4 oC for 
cyclohexane and - 25 oC for o-xylene), which makes them suitable for a freeze-drying process. 
Furthermore, both solvents could be readily emulsified to form stable oil-in-water emulsions [38, 49]. 
Solvent residuals after freeze-drying could be within the limit as defined by the International Council 
for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) as shown by 
freeze-drying organic solvents with similar vapour pressure [50]. Under stirring at 1000 rpm with an 
overhead stirrer (Eurostar digital, IKA-WERKE), the cyclohexane solution was added dropwise over 
a period of 2 minutes to the aqueous PEG-PNIPAM solution at room temperature (also once at 50 °C 
to investigate the temperature effect because the NIPAM block is known to be temperature sensitive). 
The emulsions with the volume ratios of aqueous phase to organic phase (W/O) of 1:4; 1:3 and 1:2 
were prepared. After continuously stirring for 2 minutes at 1000 rpm, the emulsions were 
homogenized for another 2 minutes using a Power Gen 1000 homogenizer by Fischer Scientific on 
setting 3. This was to produce the emulsion with smaller droplets. The emulsion was rapidly frozen in 
liquid nitrogen and placed in a CoolSafe freeze dryer by Scanvac at a condensing temperature of -90 
°C and lyophilized for two days to produce dry porous polymer containing organic nanoparticles.   
 
2. 4 Characterisation 
The emulsions were imaged on an Olympus CX41 microscope with Plan magnifying lenses. CellSens 
entry imaging software by Olympus was used for size measurements. 1H and 13C NMR spectra were 
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recorded on Bruker 400 Ultra Shield spectrometer. High resolution mass spectrometry was performed 
on a Thermo Finnigan MAT 95XP HRSM spectrometer. Particle size and Zeta-Potential was 
measured by dynamic laser scattering (DLS) analysis on a Malvern Zetasizer Nanoseries at 25 °C 
from Malvern Instruments. Polydispersity index (PDI) was obtained from Malvern software, 
indicating the particle size distribution. PDI values greater than 0.7 would indicate a very broad 
particle size distribution and the DLS method might not be suitable. The measurements were 
performed on aqueous nanoparticles suspensions with concentrations of 0.5 mg/ml. Microparticles or 
aggregates were removed by centrifugation with an Eppendorf Centrifuge 5415 D  at 3000 rpm for 3 
minutes and one minute at 3600 rpm to ensure that larger particles precipitate. 
 Scanning electron microscope (SEM) images were obtained using a Hitachi S-4800 SEM. 
The samples were coated with gold prior to imaging on an Emitech K550X Automated Sputter 
Coater. The freeze-dried samples were cut into thin slices and carefully mounted to the SEM stud 
using double adhesive carbon tape. For aqueous nanoparticles suspension, a drop of the suspension 
was deposited on a clean SEM stud and the solvent was left to evaporate before coating with gold. 
The cyro-transmission electron microscopic (cryo-TEM) analysis was performed on Tecnai G2 Spirit 
- T12 with 120 kV acceleration made by FEI, Hillsboro, USA. Powder x-ray diffraction (PXRD) data 
was collected on a PanalayticalX’Pert Pro Multi-Purpose Diffractometer in high-throughput 
transmission geometry. Cu Kα Radiation was used with Λ=1.541 Å and a divergence slit of 0.76 mm.  
Samples were pressed in a well of an aluminium plate and scanned at 40 kV and 40 mA over 5-50 ° 
2θ with a scan time of 60 min and a step size of 0.0131°. 
 
2. 5 Determination of the nanoparticles yields in the formulations 
5 mg of freeze dried material was dispersed in 10 mL deionized water and centrifuged at 3000 rpm for 
3 minutes and another minute at 3600 rpm with an Eppendorf Centrifuge 5415 D. This was to 
precipitate the larger particles by centrifuging and the nanoparticles remained in the supernatant 
solution. The precipitant was redissolved in ethanol. The concentrations of Oil Red O (OR) or other 
drug compounds were determined by UV/Vis absorption on a µQuant spectrometer by Northstar 
Scientific. Ethanol was added to the aqueous supernatant and water was then added to the ethanol 
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solution of precipitation to achieve a 1:1 v/v ethanol/water mixture. The measured absorption was 
compared to a standard curve of OR (or indomethacin) in the 1:1 v/v ethanol/water medium. Yield of 
ketoprofen and ibuprofen was measured on a 1200 series HPLC (because of no UV absorbance on the 
UV-Vis spectrum) from Agilent, comprising a vacuum degasser, quaternary pump, ALS auto-
sampler, heated column compartment and UV-Vis detector. A 300 mm by 4.6 mm phase symmetry 
silica column with a particle diameter of 5 µm and a pore size of 120 Å was used.  A flow rate of 1 
ml/min was set. The mobile phase was a mixture of hexane and isopropyl alcohol with 70 v/v % 
hexane for ketoprofen and 90% hexane for ibuprofen. All tests were carried out at 20 °C. All signals 
were UV detected at 254 nm. Data analysis was performed using Agilent Chemstation software, 
version B.02.01 (Agilent Technologies, USA).  
 
Nanoparticle yield was calculated using the following equation: 
𝑌𝑖𝑒𝑙𝑑 =
𝑚𝑁𝑃
𝑚𝑇
×  100 =
𝑚𝑆
𝑚𝑆 + 𝑚𝑃
× 100 
Where mNP is the mass of nanoparticles and mT the total mass of drug. The nanoparticle mass is 
measured from the supernatant phase after centrifuging (mS). mP indicates the mass of the drug or OR 
found in the precipitant.  Initial tests showed that PEG-PNIPAM was not UV active and did not affect 
absorption of OR or the relevant drug compounds on the UV-Vis spectra.  
 
3. Results and discussion  
 
3.1 Synthesis of PEG-PNIPAM and the polymer nanoparticles 
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Fig. 1 Preparation of lightly crosslinked branched copolymer poly(ethylene glycol)-b-(N-
isopropylacrylamide). (a) Synthesis of branched copolymer of poly(ethylene glycol)-b-(N-
isopropylacrylamide) using poly(ethylene glycol) dimer macro-azo initiator with ethylene 
diacrylamide as crosslinker in presence of  dodecanethiol at 70 oC in DMF; (b) Cartoon representation 
of the branched copolymer synthetic procedure; (c) Synthesis of small molecular diacrylaimde 
crosslinker of ethylene diacrylamide. 
 
Previously, atom transfer radical polymerization (ATRP) has been employed to synthesize branched 
copolymers together with the nanoparticles preparation [41,42]. Herein, in order to synthesize 
biocompatible nanoparticles with more convenience and high potential of scaling-up for future clinic 
applications, we have developed a much easier method by using macro-azo PEG initiator in presence 
of chain transfer agent for the synthesis of biocompatible branched  AB block copolymer PEG-
PNIPAM with varying crosslinking degrees. Three branched PEG-PNIPAM copolymers with varying 
cross-linking degrees were synthesized. Although conventional radical polymerizations instead of 
living radical polymerizations was employed, discrete soluble molecular species (soluble branched 
copolymers) in solvents such as acetone, THF etc. could still be obtained, which suggested the 
process to be a relatively controlled branching strategy [41,42]. 
It should be pointed out that when the branched copolymers were dissolved in water directly, clear 
solution could be obtained, but it was difficult to get a well defined DLS profile. This suggested that 
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the relatively low Mw PEG (eg., 6000) on the corona could not fully stabilize the uni-branched 
copolymer nanoparticles, and  resulted in dynamic aggregation-disaggregation of single nanoparticles, 
which is different from our previous reports where the MW of PEG blocks was above 1.2k. In that 
case, the uni-molecular branched copolymer nanoparticles could be stabilized by the outer PEG 
chains [41,42]. However, for the PEG-PNIPAM synthesised in this study, after the simple solvent 
removal process (see experimental section), stable and clear nanoparticles aqueous suspensions with 
well-defined DLS profiles could be obtained (Fig. 1, Fig. 2, and Table 1).  
 
 Fig. 2 (a) Dynamic laser scattering analysis of PEG-PNIPAM nanoparticles in H2O at 25 ºC after the 
solvent evaporation procedure; (b) Cryo-TEM images of nanoparticles 2 with 0.6 crosslinkage (scale 
bar: 200nm). 
Due to the relatively large size of these nanoparticles in aqueous media and their relatively small 
polymer building blocks, it is hypothesized that they aggregate into larger architectures comprised of 
smaller branched PEG-PNIPAM nanoparticles, where there are sufficient PEG chains on the corona 
to stabilize the nano-aggregates. As the degree of cross-linking increased, a slight increase in 
aggregate size was observed (Fig. 2). The nanoparticles sizes measured by DLS (number average 
sizes) were consistent with the sizes observed by cryo-TEM imaging. It was observed that upon 
heating to temperatures above the lower critical solution temperature (LCST) of N-
isopropylacrylamide, the nanoparticles further aggregate due to increase in hydrophobicity. The 
temperature induced aggregation decreased with the increased degree of cross-linking, suggesting that 
the poly(ethylene glycol) coronal arms are better in shielding the hydrophobic cores. 
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Table 1 Synthesis of lightly crosslinked branched copolymer PEG-PNIPAM and corresponding 
nanoparticles with varying amounts of ethylene diacrylamide crosslinker. 
Branched 
Block 
Copolymers 
PEG 
dimer 
NIPAM 
ethylene 
diacrylamide 
dodecanethiol DMF Temp Time 
size 
(Dh) 
1 0.1 mmol 
5 mmol 
(25 eq per 
PEG chain) 
0.06 mmol 
(0.3 eq per 
PEG chain) 
0.05 mmol 
(0.25 eq per 
PEG chain) 
7 mL 70 ºC 16 h 70 nm 
2 0.1 mmol 
5 mmol 
(25 eq per 
PEG chain) 
0.12 mmol 
(0.6 eq per 
PEG chain) 
0.05 mmol 
(0.25 eq per 
PEG chain) 
7 mL 70 ºC 16 h 81 nm 
3 0.1mmol 
5 mmol 
(25 eq per 
PEG chain) 
0.18 mmol 
(0.9 eq per 
PEG chain) 
0.05 mmol 
(0.25 eq per 
PEG chain) 
7 mL 70 ºC 16 h 96 nm 
 
 
    3.2 Hydrophobic dye OR nanoparticles by emulsion freeze-drying 
Due to their relatively hydrophobic core (hydrophobicity coming from the iso-propyl and C-C bond 
on side and main chain of PNIPAM) and hydrophilic corona (PEG), the branched PEG-PNIPAM was 
investigated as stabilizer to form emulsions and then used to produce poorly water-soluble dye and 
drug nanoparticles by the emulsion-freeze-drying approach. Emulsions are mixtures of two, normally, 
immiscible liquid phases, with one phase as droplets dispersed in the other continuous phase, and 
stabilized by surfactants [51]. Emulsions may be also formed using colloids as stabilizers, which are 
called Pickering emulsions [52]. In this study, the PEG-PNIPAM nanoparticles in water were used as 
the stabilizers to form oil-in-water (O/W) emulsions. The subsequent freeze-drying produced organic 
nanoparticles directly within the porous PEG-PNIPAM. No additional surfactant or polymer was 
used. This could in principle improve the drug loading in the nanoformulations and also reduce the 
complexity when evaluating the formulation’s cytotoxicity. The OR solution in cyclohexane or 
indomethacin (or ibuprofen and ketoprofen) solution in o-xylene (both concentration 0.5 wt%) were 
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used to form the emulsions in order to produce the relevant organic nanoparticles. The emulsions with 
80, 75 and 66% oil phase were produced with PEG-PNIPAM (1-3).  
 Oil Red O (OR), an organic dye, was chosen for initial testing because of its low water-
solubility and red colour. It was possible to form stable emulsions with 80, 75 and 66% oil phase 
using 0.3 crosslinked PEG-PNIPAM. Increasing crosslinkage and decreasing oil phase destabilized 
the emulsions. Hence using 0.6 cross-linked PEG-PNIPAM emulsions with 66% oil phase were not 
stable, while emulsion formation with 0.9 cross-linked PEG-PNIPAM was possible with 80% oil 
phase (Table 2). After freeze drying, a highly porous material was obtained [38], that could be easily 
dissolved in water to form clear red nanosuspension as shown in Fig. 3. This nanosuspension looks 
like a solution, indicating presence of small nanoparticles which do not diffract the light while the 
unprocessed OR can only float on the water surface (Fig. 3b-c). DLS measurements showed that the 
obtained OR particles were between 300 to 500 nm by Z-average (Table 2). During the formation of 
emulsion, it is hypothesized that on adding the organic solution into the aqueous PEG-PNIPAM  
solution, the aggregates of single branched copolymer PEG-PNIPAM nanoparticles (which would be 
much smaller than the nanoparticles formed after solvent evaporation procedure) in water were 
destroyed and re-dispersed, resulted in the absorption of single or small aggregates of branched 
copolymer nanoparticles outside the emulsion acting as nano-surfactant and stabilize the whole 
droplets. After the freeze-drying process, the OR particles were formed in the pores of the porous 
polymer. 
 
Fig. 3 a) Oil Red O solution in cyclohexane; b) insoluble Oil Red O in water; c) aqueous Oil Red O 
nanoparticle dispersion.   
  
ca b
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Table 2 Overview of size, zeta potential and yield of OR nanoparticles prepared by emulsion freeze 
drying.  
Cross 
linkage 
Oil Phase 
[%] 
Z-Average 
[nm] 
Intensity Peak [nm] PDI 
Zeta 
[mV] 
Yield 
[%] 
0.3 80 395 438 0.42 -54 ± 8.29 45 
0.3 75 340 980, 274 0.39 -26 ± 4.98 37 
0.3 66 423 760,231 0.35 -31 ± 6.71 50 
0.6 80 506 606, 115 0.29 -27 ± 6.47 54 
0.6 75 298 376 0.22 -18 ± 4 67 
0.6 66 not stable not stable not stable not stable not stable 
0.9 80 348 456 0.33 -25 ± 8 36 
0.9 75 not stable not stable not stable not stable not stable 
0.9 66 not stable not stable not stable not stable not stable 
 
  No discernible trend in size could be seen, since emulsions for higher cross-linked PEG-
PNIPAM could not be obtained. The Z-average sizes of OR nanoparticles shown in Table 2 are 
heavily dependent on the number of particles. Since larger particles scatter light with more intensity, 
size is shifted to larger particles in a polydisperse sample [53]. The particle size distribution may be 
shown by the peak width on DLS profiles, which may be based on scattering intensity or particle 
number. Fig. 4 shows the DLS plots by intensity. The intensity peak sizes and the relevant 
polydispersity index (PDI) are included in Table 2 as well. As Z-average only gives a single average 
number, the intensity profiles could tell more about particle size distribution. To get a clearer picture 
about particle size distribution, the DLS profiles by particle number were also given in Fig. S1.  The 
average or peak sizes by particle numbers were generally smaller that those by intensity. From both 
Fig. 4 and Fig. S1, the main particle sizes were around 100 to 300 nm with only a small percentage of 
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particles being bigger than 300 nm. This was also confirmed by SEM images of the dried 
nanosuspensions on SEM stud (Fig. 5). Figure 5a, b and c clearly show OR ellipsoid nanoparticles of 
about 100 to 200 nm.  
 
Fig. 4  DLS intensity data of nanosuspensions of a) OR nanosuspensions from different crosslinked 
PEG-PNIPAM with 80% oil phase (W/O=1/4); b) OR nanosuspensions from 0.3 crosslinked PEG-
PNIPAM with varying oil phase percentages (W/O). 
 Yield of the nanoparticles was calculated using UV/Vis measurement data. To separate 
microparticles from nanoparticles, the suspensions formed by dissolving the dry materials in water 
were centrifuged at 3000 rpm for 3 min and at 3600 rpm for another minute. The increase in speed for 
an additional minute was done to insure that the precipitates settled as a pellet and that the supernatant 
could easily be removed.   Sedimentation of particles by centrifugation is dependent on mass, shape, 
and suspension medium as postulated by Svedberg et al. [54, 55]. The obtained DLS data of the 
supernatant as well as the SEM data of the precipitated material (Fig. 5) show that the microparticles 
precipitated by centrifugation while the nanoparticles remained in the supernatant phase. The 
achieved yields of 36% - 67% may not be very high but this process required no use of additional 
surfactants [38].  
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Fig. 5 SEM images of OR nanoparticles prepared from a) 0.3 crosslinked PEG-PNIPAM from 
emulsions with  75% oil phase; b) 0.6 crosslinked PEG-PNIPAM from emulsions with  75% oil 
phase; c) 0.9 crosslinked PEG-PNIPAM from emulsions with  75% oil phase and d) the precipitated 
OR particles after centrifuging sample (a). 
 Many nanoparticle formulations experience the problem of particle agglomeration after 
processing, which is often addressed via the use of surfactants as stabilizers [33]. In this work the 
formed nanoparticles were prevented from aggregation by the porous polymer scaffold shown in Fig. 
6. The highly interconnected porous scaffold was a result of emulsion templating and ice templating. 
Because of the low atomic contrast between OR and the polymer scaffold and the possible 
encapsulation, it was very difficult to directly observe OR nanoparticles within the polymer scaffold. 
But the OR nanoparticles were stable in the PEG-PNIPAM matrix because nanoparticle suspensions 
were still produced after storing the dry materials in desiccator for 8 months (Fig. S2). 
.  
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a
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b
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10 µm
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b
16 
 
Fig. 6 SEM images of 0.6 crosslinked PEG-PNIPAM scaffolds with OR nanoparticles at different  
magnifications (a, b). The original emulsion was 75% oil phase. 
3.3 Indomethacin nanoparticles by emulsion freeze-drying 
 
 
Fig. 7 Optical microscopic images of the emulsions formed by dispersing IMC-xylene solution in 
aqueous PEG-PNIPAM solution at room temperature unless stated otherwise. a) 0.9 crosslinked PEG-
PNIPAM with 75 % oil phase (W/O =1:3); b) 0.9 crosslinked PEG-PNIPAM with 66 % oil phase 
(W/O =1:2); c) 0.6 crosslinked PEG-PNIPAM with 75 % oil phase (W/O =1:3); and d) 0.9 
crosslinked PEG-PNIPAM with 75 % oil phase (W/O =1:3) with the emulsions prepared at 50 °C.  
 It was possible to extend this approach to the preparation of poorly water soluble drugs. 
Indomethacine (IMC) was selected as a model drug for this approach as it was investigated before by 
the emulsion-freeze-drying approach [49]. IMC was dissolved in o-xylene and the organic solution 
was emulsified as the internal phase to form the O/W emulsions. Compared to OR-cyclohexane 
solution, stable emulsions for all O/W ratios and all crosslinkages of PEG-PNIPAM were formed. Fig. 
7 shows optical images of the emulsions with different W:O ratios of 1 to 3 and 1 to 2 (a and b), 
crosslinkage variation of 0.9 and 0.6 (c and a) and variations in temperature (d). The droplet sizes 
spanned from 3 µm to 20 µm with the average being around 5 µm. The very large droplets in Fig. 7d 
 
a b 
c d 
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were likely a result of an increasing instability of the emulsion due to the higher preparation 
temperature at 50 °C.  The average droplet size decreased slightly when the volume of oil phase was 
decreased. The crosslinkage level of PEG-PNIPAM did not seem to have significant influence on 
droplet size.  
Table 3 Overview of size, zeta potential and yield of IMC nanoparticles. 
Cross 
linkage 
Oil Phase 
[%] 
Z-Average 
[nm] 
Intensity Peak 
[nm] 
PDI 
Zeta 
[mV] 
Yield 
[%] 
0.3 80 480 472 0.22 -17 ± 4 40 
0.3 75 475 486 0.18 -11 ± 4 23 
0.3 66 484 396, 192 0.36 -18 ± 5 28 
0.6 80 551 408 0.35 -14 ± 4 46 
0.6 75 476 492, 148 0.51 -13 ± 4 38 
0.6 66 552 713, 219 0.43 -14 ± 4 40 
0.9 80 
454 
(1038)* 
472, 93 0.33 
-11 ± 4 
(-16 ± 3)* 
53 
(38)* 
0.9 75 507 545, 163 0.33 -10 ± 3 43 
0.9 66 470 484, 112 0.38 - 7 ± 3 64 
 
Note: *emulsion prepared at 50 °C 
 
 The size, zeta potential, PDI and yield of IMC nanoparticles are given in Table 3. The IMC 
yields increased to 64% with increasing crosslinkage. Lower percentage of oil phase in the emulsions 
led to decrease in nanoparticle yield for 0.3 and 0.6 crosslinked PEG-PNIPAM, while no obvious 
trend was observed for the 0.9 crosslinked PEG-PNIPAM. The DLS and zeta potential measurements 
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included three separate runs, from which the average values were calculated and used. The zeta 
potential exhibited by OR nanoparticle was roughly two times that for IMC nanoparticle. Zeta 
potential was found to be in the same domain of -10 to -15 mV for IMC and -20 to -30 mV for OR 
particles. Z-average data showed that IMC nanoparticles with sizes between 450 and 550 nm could be 
formed.  Generally OR particles tended to be smaller in size than IMC particles.  
 Particle size distributions by intensity (Fig. S3) and by number (Fig. S4) were both measured. 
The presence of single peak or multiple peaks was the same for the DLS profiles either by intensity or 
number. However, for polydispersed samples, the shape of the profiles was different. Larger particles 
generated higher peak intensity in the intensity plot (Fig. S3) while the smaller sized particles gave 
higher number percentage peak in the number plot (Fig. S4). There was no obvious trend for the 
impact on particle sizes from ratio of water to oil and polymer crosslinkage. The impact on particle 
size distribution was quite small as well. It should be mentioned that the IMC nanoparticles within the 
PEG-PNIPAM scaffold were also highly stable. After the storage of IMC particles-PEG-PNIPAM in 
desiccator for 8 months, the materials could be still readily dissolved in water and producing aqueous 
IMC nanoparticles dispersion with similar particle size and particle size distribution (Fig. S5). 
 
Fig. 8 SEM images of IMC nanoparticles formed from a) 0.6 crosslinked PEG-PNIPAM emulsion 
with  80% oil phase (W/O=1/4); b) 0.6 crosslinked PEG-PNIPAM emulsion with  75% oil phase 
10.0 µm 
µµmµm 
a 
10.0 µm 
µµmµm 
b 
1.00 µm 
µµmµm 
c d
c 
3.00 µm 
µµmµm 
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(W/O=1/3); c) 0.6 crosslinked PEG-PNIPAM emulsion with  66% oil phase (W/O=1/2);  and d) the 
precipitated IMC microparticles after centrifuging sample (a). 
 SEM images of IMC nanoparticles (Fig. 8) were obtained. Fig. 8a and 8c show ellipsoid 
shaped particles ranging from 300 nm to 1000 nm. This wide range can be explained by comparison 
with the DLS data in Figure S3a, which showed that particles incorporated within 0.6 crosslinked 
PEG-NIPAM exhibited a broad size distribution from 100 to 1000 nm.  Figure 8b shows needle 
shaped IMC nanoparticles around 1000 nm, although the same preparation method was used. These 
findings are considerably different from the measured DLS data. An explanation could be that the 
nanoparticles started to crystalize while in solution or on the SEM stud during solvent evaporation.  
Microparticles of IMC were precipitated by centrifugation and observed under SEM as well (Fig. 8d). 
  SEM imaging of the freeze-dried porous materials was also performed. The highly porous 
structure was observed for all the samples (Fig. 9 and Fig. S6). Like the porous materials containing 
OR nanoparticles (Fig. 6), similar droplet templated pores with high interconnectivity could be 
observed. The pores in Fig. 9b show a diameter range of 2 to 5 µm, similar to the droplet sizes 
measured in Fig. 7. The polymer scaffold with IMC nanoparticles seemed to be well defined and 
smooth, while the ridges in Fig. 6 clearly showed a more fibrous structure for the scaffold with OR 
nanoparticles. As for OR, it was very difficult to observe IMC nanoparticles in the scaffold directly. 
Changes in crosslinkage or O:W ratio did not change pore size or size distribution significantly, 
contrary to the previous report [56]. This is likely due to the fact that all emulsions were formed by 
homogenization in this study, which predominantly influenced droplet shape and size.  
 
Fig. 9 SEM images of 0.9 crosslinked PEG-PNIPAM scaffold with IMC nanoparticles at different 
magnifications (a, b). The original emulsion was 75% oil phase. 
 
20.0 µm 
µµmµm 
a 
5.00 µm 
b 
20 
 
 
 Generally, amorphous drugs exhibit higher solubility and dissolution rate, which is favourable 
for drug applications [57]. The crystallinity of IMC nanoparticles was therefore examined. It is known 
that IMC has more than one polymorphic form. The two most stable ones are α- and γ-IMC, with 
melting points of 155 °C and 161 °C respectively [58]. PXRD patterns of PEG-PNIPAM, IMC and 
their composites were recorded and given in Fig. 10. Comparison with predicted PXRD data from 
single crystal data (Fig. S7) indicated that the IMC used in this study was γ-Indomethacin (Fig. 10b) 
[59,60]. PXRD data of IMC nanoparticles in 0.3 crosslinked PEG-PNIPASM showed only three sharp 
peaks at 15 o, 20 o and 25 o with low intensity (Fig. 10c), similar to the PXRD pattern of PEG-
PNIPAM (Fig. 10a). This suggested that the incorporated IMC nanoparticles were not highly 
crystalline. Similar patterns were recorded for the IMC particles incorporated into the 0.6 and 0.9 
crosslinked PEG-PNIPAM (Fig. S8). Polymers typically form amorphous structures, however 
semicrystaline structures which exhibit amorphous and crystalline regions are known for polymers as 
well. Semicrystalinity accounts for the sharp peaks in the PXRD, as well as the broad underlying 
peak, the so called ‘halo’, from 15° to 30° (Fig. 10a). In order to identify the phase of IMC particles 
more clearly, the IMC nanoparticles were separated from the polymer by centrifuging at 13000 rpm 
for 5 minutes. A control experiment with aqueous polymer solution at this speed showed no 
precipitation of polymer PEG-PNIPAM. Fig. 10d shows the similar PXRD pattern as Fig. 10c (non-
centrifuged), but with the peak intensity significantly decreased. This led us to the conclusion that 
these peaks were more likely the artefacts of PEG-PNIPAM adsorbed to IMC particles and 
precipitated together. This indicated that amorphous IMC nanoparticles were produced by this 
approach.  
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Fig. 10 PXRD patterns of a) raw block copolymer PEG-PNIPAM;b) as-purchased IMC; c) IMC 
particles with 0.3 crosslinked PEG-PNIPAM; d) IMC nanoparticles obtained after centrifugation of 
the nanosuspension at 13000 rpm for 5 minutes. 
 
 3.4 Further extension to ketoprofen and ibuprofen nanoparticles 
In order to demonstrate the versatility of the emulsion-freeze-drying approach, two more drugs, 
ketoprofen and ibuprofen were processed using the same procedure. Since the highest yield for IMC 
was achieved using 0.9 crosslinked PEG-PNIPAM and 66 % o-xylene, these conditions were also 
used for ketoprofen and ibuprofen. It was possible to form stable emulsions with droplet sizes 
between 5 to 25 µm (Fig. S9, Fig. S10), as already observed for emulsions containing indomethacin 
(Fig. 7b). After freeze-drying, porous white materials were obtained for both ketoprofen and 
ibuprofen, which were dissolved in water to produce a clear suspension without any precipitates 
observed. DLS measurements were performed without any pre-treatment of the nanosuspensions.  
Zeta potential was quiet similar for both drugs at -8 ± 19 mV (ibuprofen) and – 8 ± 23 mV 
(ketoprofen). The DLS profiles by intensity (Fig. S11) gave the peak size 198 nm for ibuprofen and 
211 nm for ketoprofen.  The particle size distribution was calculated to be 1.32 for ketoprofen and 
1.15 for ibuprofen.  A narrower particle size distribution was observed if the DLS profiles were 
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plotted by particle number percentage, with the peak size much smaller at 60 nm for ketoprofen and 
100 nm for ibuprofen (Fig. S12). This indicates that a 100% yield of nanoparticles for ketoprofen and 
ibuprofen was achieved by the emulsion-freeze-drying approach. 
 
4 Conclusions 
Lightly crosslinked branched block copolymer PEG-PNIPAM has been synthesized. Well-defined 
nanoparticles could be obtained by mixing its organic solution (e.g., tetrahydrofuran, acetone, etc.) 
and water and followed by evaporation of the organic solvent. The polymer could be easily dissolved 
in water to get clear solutions with PEG-PNIPAM nanoparticles present. Oil-in-water emulsions were 
formed using the PEG-PNIPAM nanoparticles as stabilizers. By dissolving hydrophobic dye or poorly 
water-soluble drugs in the formed oil-in-water emulsion, an emulsion-freeze-drying approach was 
employed to produce dye/drug nanoparticles in situ within the dry porous PEG-PNIPAM scaffolds. 
The scaffolds prevented aggregation of the dye/drug nanoparticles in solid state and could be readily 
dissolved in water to generate aqueous nanoparticles dispersion. The use of PEG-PNIPAM as both 
surfactant and polymeric support is highly efficient and versatile, as demonstrated by the hydrophobic 
dye Oil Red O and several drugs. The yield of nanoparticles varied but could achieve 100% for both 
ketoprofen and ibuprofen. Both the block copolymer nanoparticles and the emulsion-freeze-drying 
approach are highly promising in addressing the poor water solubility problem and potential use in 
nanomedicine for treatment. 
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